Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation. This development will allow certain unlisted shares of the company to be converted into H shares, which will be listed and traded on the Main Board of the Hong Kong Stock Exchange. This move is expected to enhance the company’s market presence and liquidity, providing more opportunities for investors and potentially strengthening its position in the biopharmaceutical industry.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of high-quality biologic medicines. The company operates primarily in the biopharmaceutical industry, offering products and services related to the research and production of therapeutic proteins and monoclonal antibodies.
Average Trading Volume: 1,431,220
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.78B
See more data about 2696 stock on TipRanks’ Stock Analysis page.